Apixaban Tablet, Film Coated
Product Images NDC 14445-149

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Apixaban (NDC 14445-149). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Indoco Remedies Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig3 (Fig3)

This figure is a forest plot showing the fold change and 90% confidence intervals of pharmacokinetic parameters (Cmax and AUC) for apixaban in various populations compared to reference groups. It includes comparisons for renal impairment, age, body weight, and hepatic impairment, along with dosing recommendations based on these parameters.*

FDA Label Image

Str (Structure)

Chemical structure of apixaban, a prescription oral tablet active ingredient. The diagram shows the molecular arrangement of apixaban's atoms and bonds as used in the pharmaceutical product by Indoco Remedies Limited.*

FDA Label Image

Apixaban-2.5-180 (Apixaban 2.5 180s)

Apixaban Tablets 2.5 mg film-coated tablets label from Indoco Remedies Limited. The label shows storage instructions, a barcode, and states that each tablet contains 2.5 mg apixaban. It indicates a quantity of 180 tablets and includes directions for pharmacists to dispense the medication guide to patients.*

FDA Label Image

Apixaban-2.5-500 (Apixaban 2.5 500s)

Apixaban 2.5 mg film-coated tablets label showing packaging for oral human prescription drug by Indoco Remedies Limited. The label indicates a quantity of 500 tablets and includes storage instructions, dosage directions referring to the package insert, and the manufacturer address in Goa, India. A barcode and NDC number 14445-149-05 are also visible.*

FDA Label Image

Apixaban-2.5-60 (Apixaban 2.5 60s)

Apixaban Tablets 2.5 mg film-coated tablets package label showing quantity of 60 tablets. Label includes NDC 14445-149-60 and indicates prescription use only. Manufactured by Indoco Remedies Limited, India, with storage instructions and a barcode visible.*

FDA Label Image

Apixaban-2.5-carton (Apixaban 2.5 Carton)

Packaging label for Apixaban Tablets 2.5 mg, film-coated tablets for oral use. The label includes dosing strength, instructions to dispense the accompanying Medication Guide, and the labeler Indoco Remedies Limited. It features a barcode, NDC 14445-140-14, and sections with dosage, manufacturer information, and regulatory notices. The design uses purple and black text on a white background with a purple band.*

FDA Label Image

Apixaban-5mg-180 (Apixaban 5 180s)

Apixaban Tablets 5 mg film-coated oral tablets packaging label from Indoco Remedies Limited. The label includes storage instructions, dosage information, and a barcode. It indicates a package size of 180 tablets and the requirement to dispense the accompanying Medication Guide.*

FDA Label Image

Apixaban-5mg-500 (Apixaban 5 500s)

Apixaban 5 mg tablets packaging label for oral administration, containing 500 film-coated tablets. Manufactured by Indoco Remedies Limited, the label includes dosage storage instructions, a pharmacy code, and directions for pharmacists to dispense with a medication guide. The NDC is 14445-150-05.*

FDA Label Image

Apixaban-5mg-60 (Apixaban 5 60s)

Label for Apixaban Tablets 5 mg film-coated oral tablets by Indoco Remedies Limited. The label specifies a quantity of 60 tablets and includes NDC 14445-150-60. It provides storage instructions, usage notes, and a barcode. The label is marked for prescription use only.*

FDA Label Image

Apixaban-5mg-carton (Apixaban 5 Carton)

Apixaban 5 mg film-coated tablets packaging label from Indoco Remedies Limited. The label includes dosage strength, tablet form, oral route, and instructions to dispense the accompanying medication guide. It features a barcode and space for GTIN, expiration, lot, and UID details.*

FDA Label Image

Fig2 (Fig2)

A scatter plot chart illustrating the fold change and 90% confidence interval in pharmacokinetic parameters Cmax and AUC caused by various interacting drugs, including ketoconazole, clarithromycin, diltiazem, naproxen, and rifampin, relative to a reference for apixaban. The x-axis represents change relative to reference from 0.5 to 2.0 fold.*

FDA Label Image

Fig4 (Fig4)

A Kaplan-Meier survival curve showing the proportion of subjects with stroke or systemic embolism over 36 months for two groups: one receiving apixaban (Eliquis) and the other receiving warfarin. The graph indicates lower event rates in the apixaban group (212 events/9120 subjects) compared to the warfarin group (265 events/9081 subjects). The x-axis represents time in months, while the y-axis shows the cumulative proportion of subjects experiencing the event. A hazard ratio (HR) of 0.79 with a p-value of 0.0114 is noted. The number of subjects at risk is listed below the x-axis for both groups at several time points.*

FDA Label Image

Fig5 (Fig5)

A forest plot comparing the hazard ratios with 95% confidence intervals for apixaban versus warfarin across various patient subgroups. The chart includes subgroups by prior warfarin use, age, sex, weight, prior stroke or TIA, diabetes status, CHADS2 score, creatinine clearance, geographic region, and aspirin use at randomization. The x-axis shows relative risk favoring apixaban or warfarin based on the hazard ratio values.*

FDA Label Image

Figure1 (Figuere1)

A forest plot comparing the hazard ratios of apixaban versus warfarin across various patient subgroups. The left side lists subgroups such as age, sex, weight, prior conditions, and geographic region, with corresponding event rates and patient counts for apixaban and warfarin. The right side graphically displays hazard ratios with 95% confidence intervals, indicating whether outcomes favored apixaban or warfarin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.